Drug Type Protein drugs |
Synonyms- |
Target |
Mechanism TFR2 agonists(transferrin receptor 2 agonists), TfR1 stimulants(Transferrin receptor protein 1 stimulants) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Beta-Thalassemia | Phase 3 | NL | 21 Mar 2019 | |
Congenital Atransferrinemia | Phase 3 | DE | 01 Dec 2010 | |
Congenital Atransferrinemia | Phase 3 | IT | 01 Dec 2010 | |
Congenital Atransferrinemia | Phase 3 | ES | 01 Dec 2010 |
Phase 2/3 | 5 | ktqonmznex(hsuyjgkacn) = slightly lower than the mean dose-normalized AUC∞ at a single dose in year 1, indicating non-linearity xbolouilne (auuzcjkniq ) View more | Positive | 14 May 2024 | |||
(Control (No Treatment)) | |||||||
Phase 2/3 | 5 | beoxdijqpv(oyarvtlcud) = xtceapfayl gnqijxjetk (deciwyavey ) | Positive | 11 Dec 2023 |